M&G Investment Management’s Indivior Pharmaceuticals INDV Stock Holding History

M&G Investment Management’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-33,058	Closed	-$71.7M	–	356
2023 Q3	$71.7M	Buy	33,058 +1,008	+3%	+$23K	0.32%	55
2023 Q2	$74.2M	Buy	+32,050	New	+$735K	0.3%	65

Other funds holding INDV

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

M&G Investment Management's INDV Position: Q4 2023 in Review

M&G Investment Management sold out of Indivior Pharmaceuticals (INDV) in Q4 2023, closing a stake of 33,058 shares — an estimated $71.7M sold.

M&G Investment Management first reported a position in INDV in Q2 2023 and held it in 2 quarters. The position peaked at $74.2M in Q2 2023. 76 funds tracked by Wall St. Rank hold INDV as of Q4 2023.

M&G Investment Management reported no remaining Indivior Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
M&G Investment Management sold 33,058 Indivior Pharmaceuticals shares in Q4 2023, an estimated $71.7M.
M&G Investment Management first reported a position in Indivior Pharmaceuticals in Q2 2023 and held it in 2 quarters.
M&G Investment Management's Indivior Pharmaceuticals position peaked at $74.2M in Q2 2023.
76 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q4 2023.

Based on M&G Investment Management's 13F filing for Q4 2023, filed 8 Feb 2024.